证券代码：688265 证券简称：南模生物 公告编号：2025-071 回购股份的基本情况 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 23 日至 2024 年 5 月 22 日期间通过集中竞价交易方式累计回购股份 788,912 股， 占公司总股本的 1.0119%。前述回购的股份拟用于维护公司价值及股东权益，将 在披露回购实施结果公告（即 2024 年 5 月 23 日）12 个月后采用集中竞价的方 式出售，并在披露股份回购实施结果公告日后 3 年内完成转让；若公司未能在上 述期限内完成转让，尚未转让的已回购股份将予以注销。 减持计划的实施结果情况 2025 年 8 月 29 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《关于回购股份集中竞价减持股份计划公告》（公告编号：2025-054），公司计 划按照市场价格，通过集中竞价交易方式减持回购股份合计不超过 779,635 股 （不超过公司总股本的 1%），减持期间为自前述公告披露之日起 15 个交易日后 的 3 个月内。若减持期间公司发生派发红利、送红股、转增股本、增发新股、配 股等导致股份变动事 ...

Group 1 - The core point of the article is that Nanmo Biological announced that as of November 30, 2025, the company has not reduced its repurchased shares [2]

证券代码：688265 证券简称：南模生物 公告编号：2025-070 上海南方模式生物科技股份有限公司 关于回购股份集中竞价减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 回购股份的基本情况 上海南方模式生物科技股份有限公司（以下简称"公司"）于 2024 年 2 月 23 日至 2024 年 5 月 22 日期间通过集中竞价交易方式累计回购股份 788,912 股，占 公司总股本的 1.0119%。前述回购的股份拟用于维护公司价值及股东权益，将在 披露回购实施结果公告（即 2024 年 5 月 23 日）12 个月后采用集中竞价的方式 出售，并在披露股份回购实施结果公告日后 3 年内完成转让；若公司未能在上述 期限内完成转让，尚未转让的已回购股份将予以注销。 减持计划的进展情况 2025 年 8 月 29 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《关于回购股份集中竞价减持股份计划公告》（公告编号：2025-054），公司计划 按照市场价格，通过集 ...

Core Viewpoint - Nanmo Biology focuses on the research, production, sales, and related technical services of genetically modified animal models, primarily using mice, rats, and nematodes as model organisms [1] Company Overview - The company utilizes gene editing technology to insert, delete, or modify endogenous genes, creating biological models that simulate specific physiological, pathological, and cellular characteristics of humans [1] - The genetically modified animal models produced by the company mainly refer to genetically modified mouse models [1] Strategic Positioning - The company does not engage in any technical collaboration or strategic partnership with Yizhiming [1]

Group 1 - The company, Nanmo Biology, reported an increase in the number of shareholders from 6,522 as of June 30, 2025, to 6,687 as of September 30, 2025 [2]

Core Viewpoint - Nanmo Biology (688265.SH) focuses on the research, production, sales, and related technical services of genetically modified animal models, primarily using mice, rats, and nematodes as model organisms [1] Group 1: Company Overview - The company utilizes gene editing technology to insert, delete, or modify specific DNA segments, creating biological models that simulate human physiological, pathological, and cellular characteristics [1] - The genetically modified animal models produced by the company mainly refer to genetically modified mouse models [1] Group 2: Strategic Positioning - The company does not engage in any technical collaboration or strategic partnership with Yizhiming [1]

Core Viewpoint - Nanmo Bio has experienced significant stock price fluctuations in 2023, with a year-to-date increase of 79.28% but recent declines in the short term [1] Company Overview - Nanmo Bio, officially known as Shanghai Nanmo Biological Technology Co., Ltd., was established on September 20, 2000, and went public on December 28, 2021 [1] - The company specializes in the research, production, and sales of genetically modified animal models and related technical services [1] - Revenue composition includes standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and others (0.91%) [1] Financial Performance - For the period from January to September 2025, Nanmo Bio reported a revenue of 303 million yuan, representing a year-on-year growth of 14.29% [2] - The net profit attributable to shareholders reached 26.76 million yuan, showing a substantial year-on-year increase of 276.14% [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 2.53% to 6,687, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - Since its A-share listing, Nanmo Bio has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Tianhong Medical Health A is a new entrant, holding 377,400 shares [3]

Group 1 - The core viewpoint of the news is that Nanmo Biotechnology experienced a decline in stock price and significant financing activity, indicating a high level of market interest and potential volatility [1] - On November 12, Nanmo Biotechnology's stock fell by 1.59%, with a trading volume of 53.85 million yuan. The net financing buy was -10.10 million yuan, with a total financing balance of 57.63 million yuan, accounting for 1.68% of the circulating market value [1] - The company has a high financing balance, exceeding the 60th percentile of the past year, indicating a relatively elevated level of leverage in the market [1] Group 2 - As of September 30, the number of shareholders for Nanmo Biotechnology increased by 2.53% to 6,687, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - For the period from January to September 2025, Nanmo Biotechnology reported a revenue of 303 million yuan, representing a year-on-year growth of 14.29%, and a net profit attributable to shareholders of 26.76 million yuan, which is a significant increase of 276.14% year-on-year [2] Group 3 - Since its A-share listing, Nanmo Biotechnology has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3] - As of September 30, 2025, Tianhong Medical Health A became the tenth largest circulating shareholder with 377,400 shares, while a previous major shareholder, Rongtong Health Industry Flexible Allocation Mixed A/B, exited the top ten list [3]

Group 1 - The core viewpoint of the news is that Nanmo Bio experienced a slight decline in stock price and had notable financing activities on November 11, indicating a high level of financing balance relative to its market value [1] - On November 11, Nanmo Bio's financing buy amount was 1.87 million yuan, while the financing repayment was 2.23 million yuan, resulting in a net financing buy of -0.36 million yuan [1] - As of November 11, the total financing and securities lending balance for Nanmo Bio was 67.73 million yuan, which accounts for 1.95% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, the number of shareholders for Nanmo Bio was 6,687, an increase of 2.53% from the previous period, while the average circulating shares per person decreased by 2.47% to 11,658 shares [2] - For the period from January to September 2025, Nanmo Bio achieved an operating income of 303 million yuan, representing a year-on-year growth of 14.29%, and a net profit attributable to the parent company of 26.76 million yuan, which is a significant increase of 276.14% year-on-year [2] Group 3 - Since its A-share listing, Nanmo Bio has distributed a total of 30.04 million yuan in dividends, with 10.00 million yuan distributed over the past three years [3] - As of September 30, 2025, Tianhong Medical Health A became the tenth largest circulating shareholder with 377,400 shares, marking its entry as a new shareholder, while Rongtong Health Industry Flexible Allocation Mixed A/B exited the top ten circulating shareholders [3]

Core Viewpoint - Nanmo Bio experienced a slight decline in stock price, with significant financing activity indicating a high level of market interest and liquidity [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Nanmo Bio achieved a revenue of 303 million yuan, representing a year-on-year growth of 14.29% [2]. - The net profit attributable to shareholders for the same period was 26.76 million yuan, showing a substantial year-on-year increase of 276.14% [2]. Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Nanmo Bio reached 6,687, an increase of 2.53% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 2.47% to 11,658 shares [2]. - The company has distributed a total of 30.04 million yuan in dividends since its A-share listing, with 10.00 million yuan distributed over the past three years [3]. Group 3: Financing and Margin Data - On November 6, 2023, Nanmo Bio recorded a financing buy-in of 2.72 million yuan, while the financing repayment amounted to 4.31 million yuan, resulting in a net financing outflow of 1.59 million yuan [1]. - The total margin balance for Nanmo Bio as of November 6, 2023, was 73.85 million yuan, accounting for 2.10% of its market capitalization, which is above the 70th percentile of the past year [1]. - There were no short sales or borrowings on November 6, 2023, indicating a lack of bearish sentiment in the market [1].